Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

633P - Mutational landscape differences between young-onset and older-onset prostate cancer patients

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Prostate Cancer

Presenters

Yong Wang

Citation

Annals of Oncology (2021) 32 (suppl_5): S626-S677. 10.1016/annonc/annonc702

Authors

Y. Wang1, Z. Liu1, T. Yang2, H. Wang3, F. Lou3, S. Cao3, Y. Niu1

Author affiliations

  • 1 Department Of Urology, The Second Hospital of Tianjin Medical University, 300000 - Tianjing/CN
  • 2 Department Of Medicine, Beijing Acornmed Biotechnology Co., Ltd., 100176 - Beijing/CN
  • 3 Medicine, 5Acornmed Biotechnology Co., Ltd., 100021 - Beijing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 633P

Background

Prostate cancer (Pca) is the second common cancer among male worldwide. In recent years, the incidence and mortality in China have gradually increased. Most tumours profiled in these studies were obtained from patients from Caucasians population, while conditions in other races remain unclear.

Methods

Somatic and germline mutations were identified via targeted next generation sequencing with Acornmed panel including 808 genes associated with tumor development. Sequencing data were analyzed to call tumor specific single nucleotide variants (SNV), small insertions and deletions (InDels), copy number alterations (CNA) and chromosomal rearrangements.

Results

A total 3158 genomic alterations (GA) were identified in 429 Pca patients, including missense mutations(61%), followed by frameshift indel (22%), inframeshift indel (2%),stop gain (6%) , copy number loss (6%) copy number gain (2%) and splicing (2%) stop loss (0.1%) mutations. Germline pathogenic or likely pathogenic mutations occurred in DNA damage repair genes 13%. The median age of patients with Pca was 55 (range 31-59) in the patients who were <60 and 70 (range 60-91) in the patients who were ≥60. The GA/sample in patients who were ≥60 were higher (3.8 in <60 vs. 7.8 in ≥60). P/LP mutations in DDR genes were more common in early-onset Pca < 60 (23% in <60 vs. 12% in ≥60, p=0.024). In addition, the somatic spectrum was different between patients who were <60 and ≥60 years of age. The most common mutations detected in patients with early-onset Pca < 60 were TP53 (25%), AR (17%), CDK12 (9%), FOXA1 (9%) and PTEN (9%) vs. FOXA1 (16%), AR (14%), TP53 (14%), CDK12 (11%) and SPOP (9%) in patients who were ≥60 years of age. Frequency of TP53 mutations were significantly higher in patients < 60 years of age (p=0.04), while FOXA1 mutations were higher in patients ≥60 years of age.

Conclusions

To our knowledge, this is a first systematic comparison study in Pca patients in the patients who were < 60 and ≥60 years of age. At a population level, there were notable differences observed in germline and somatic variants in two cohorts. Those molecular profiling may predict the benefit of targeted therapy and immunotherapy in patients with Pca and that could potentially be used in clinical trials.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Y. Niu.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.